(Total Views: 784)
Posted On: 06/21/2020 3:25:23 PM
Post# of 157343
“So, with those caveats having been disclosed, and my admission these are completely blue sky, spit-balled numbers, and using an authorized share count of 800M -- NP's 2021 $9B revenue estimate equates to $11.25 per share.”
NP has stated that the COVID19 indication will most likely be licensed. This means that a decent portion of revenue will be shared with that partner, thus, reducing the amount of revenue that comes directly to CYDY. If leronlimab proves effective, like you said, it won’t need much marketing, but what will the licensing percentage be? 50%? Basically, the $11.25 per share may be more like $6 per share.
NP has stated that the COVID19 indication will most likely be licensed. This means that a decent portion of revenue will be shared with that partner, thus, reducing the amount of revenue that comes directly to CYDY. If leronlimab proves effective, like you said, it won’t need much marketing, but what will the licensing percentage be? 50%? Basically, the $11.25 per share may be more like $6 per share.
(0)
(0)
